Welcome to our dedicated page for Veru news (Ticker: VERU), a resource for investors and traders seeking the latest updates and insights on Veru stock.
Veru Inc. (NASDAQ: VERU) is a late clinical-stage biopharmaceutical company advancing innovative therapies for cardiometabolic diseases, oncology, acute respiratory distress syndrome (ARDS), and sexual health. This page provides investors and stakeholders with timely updates on clinical trial progress, regulatory milestones, and strategic initiatives.
Access the latest Veru news, including press releases on drug development programs like enobosarm for muscle preservation during weight loss and sabizabulin for inflammatory conditions. Stay informed about earnings updates, partnership announcements, and scientific advancements across Veru's diversified pipeline.
All content is sourced directly from company communications and vetted financial news outlets. Bookmark this page for streamlined access to critical updates affecting Veru investment analysis and market positioning.
Veru Inc. (NASDAQ: VERU), a biopharmaceutical company, will host a conference call and audio webcast on May 11, 2023, at 8:00 a.m. ET to discuss its fiscal 2023 Q2 financial results and provide a business update. Interested investors can access the call through the company's website or by dialing specified telephone numbers. Veru is focused on developing treatments for breast cancer and SARS-CoV-2, with ongoing clinical trials for its candidates, including enobosarm for metastatic breast cancer and sabizabulin for COVID-19. Sabizabulin has shown a statistically significant 51.6% reduction in deaths in a Phase 3 trial. The company plans to conduct further trials and has received Fast Track designation from the FDA for its COVID-19 treatment.
Veru Inc. (NASDAQ: VERU) has announced the sale of its ENTADFI® business to Blue Water Vaccines, Inc. for a total of $20 million, with potential additional earnings of up to $80 million based on sales milestones. The deal includes an upfront payment of $6 million and scheduled payments of $4 million in fiscal 2023 and $10 million in fiscal 2024. This move aims to provide Veru with the financial flexibility needed to further develop its drug candidates, namely enobosarm for metastatic breast cancer and sabizabulin for SARS-CoV-2 related complications, with Phase 3 data anticipated in 2024. The company is also advancing multiple studies focusing on infectious diseases and oncology.
Veru Inc. (NASDAQ: VERU) has announced a Purchasing Agreement with Afaxys Group Services, LLC (AGS) to supply its FC2 Female Condom® through AGS's Group Purchasing Organization. This agreement aims to provide affordable contraceptive options to approximately 31 million individuals relying on community health services. The FC2 Female Condom is FDA-approved and serves dual functions: preventing unintended pregnancies and reducing sexually transmitted infections, including HIV/AIDS. A preferred pricing model will ensure access for healthcare providers serving underrepresented populations. Dr. Mitchell Steiner, Veru's CEO, highlighted the agreement's role in enhancing accessibility to sexual and reproductive health services.
FAQ
What is the current stock price of Veru (VERU)?
What is the market cap of Veru (VERU)?
